These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 2405727)

  • 1. Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala.
    Navin TR; Arana BA; Arana FE; de Mérida AM; Castillo AL; Pozuelos JL
    Am J Trop Med Hyg; 1990 Jan; 42(1):43-50. PubMed ID: 2405727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute pancreatitis associated with the administration of meglumine antimonate for the treatment of visceral leishmaniasis.
    de Lalla F; Pellizzer G; Gradoni L; Vespignani M; Franzetti M; Stecca C
    Clin Infect Dis; 1993 May; 16(5):730-1. PubMed ID: 8507769
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis.
    Convit J; Castellanos PL; Rondon A; Pinardi ME; Ulrich M; Castes M; Bloom B; Garcia L
    Lancet; 1987 Feb; 1(8530):401-5. PubMed ID: 2880213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A comparative study between sodium stibogluconate BP 88R and meglumine antimoniate in the treatment of cutaneous leishmaniasis. I. The efficacy and safety].
    Saldanha AC; Romero GA; Merchan-Hamann E; Magalhães AV; Macedo Vde O
    Rev Soc Bras Med Trop; 1999; 32(4):383-7. PubMed ID: 10495667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose glucantime therapy in Leishmania viannia braziliensis (Lvb) infections.
    Costa JM; Marsden PD
    Rev Soc Bras Med Trop; 1988; 21(2):85-6. PubMed ID: 3249826
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe leucopenia during treatment of visceral leishmaniasis.
    Hiçsönmez G; Jama H; Ozsoylu S
    Trans R Soc Trop Med Hyg; 1988; 82(3):417. PubMed ID: 3232176
    [No Abstract]   [Full Text] [Related]  

  • 7. Glucantime fever with parenteral meglumine antimonate in patients of cutaneous leishmaniasis.
    Rashid BN; Tabassum S; Ullah Rao MS; Masood S; Abbas MM; Mumtaz MJ
    J Coll Physicians Surg Pak; 2010 Jul; 20(7):496. PubMed ID: 20642959
    [No Abstract]   [Full Text] [Related]  

  • 8. [Torsades de pointes during treatment of leishmaniasis with meglumine antimoniate].
    Castelló Viguer MT; Echánove Errazti I; Ridocci Soriano F; Esteban Esteban E; Atienza Fernández F; Cuesta Estellés G
    Rev Esp Cardiol; 1999 Jul; 52(7):533-5. PubMed ID: 10439681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial.
    Velez I; Agudelo S; Hendrickx E; Puerta J; Grogl M; Modabber F; Berman J
    Ann Intern Med; 1997 Feb; 126(3):232-6. PubMed ID: 9027276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of patients with Leishmania (Viannia) braziliensis infection and treated with Glucantime.
    Netto EM; Marsden PD; Llanos-Cuentas EA; Costa JM; Cuba CC; Barreto AC; Badaró R; Johnson WD; Jones TC
    Trans R Soc Trop Med Hyg; 1990; 84(3):367-70. PubMed ID: 2260171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse cutaneous leishmaniasis acquired in Peru.
    Franke ED; Lucas CM; Tovar AA; Kruger JH; De Rivera MV; Wignall FS
    Am J Trop Med Hyg; 1990 Sep; 43(3):260-2. PubMed ID: 2221221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucantime-resistant visceral leishmaniasis in immunocompromised patients.
    Verdejo J; Alvar J; Polo RM; González-Lahoz JM
    Am J Med; 1988 Jul; 85(1):128. PubMed ID: 3389377
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens.
    Oliveira-Neto MP; Schubach A; Mattos M; Gonçalves-Costa SC; Pirmez C
    Pathol Biol (Paris); 1997 Jun; 45(6):496-9. PubMed ID: 9309267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
    Andersen EM; Cruz-Saldarriaga M; Llanos-Cuentas A; Luz-Cjuno M; Echevarria J; Miranda-Verastegui C; Colina O; Berman JD
    Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pancreatitis during treatment of leishmaniasis with n-methylglucamine antimoniate in a subject infected with HIV].
    Trinchieri V; Ferone U; Monacelli M; Isceri L; Proietti F; Sorice F
    Riv Eur Sci Med Farmacol; 1996; 18(2):49-51. PubMed ID: 9213843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retention of antimony in hair during leishmaniasis treatment.
    Dorea JG; Merchan-Hamann E; Ryan DE; Holzbecher J
    Clin Chim Acta; 1989 Feb; 179(3):341-5. PubMed ID: 2714007
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro and in vivo anti-leishmanial activity of chlorpromazine alone and combined with N-meglumine antimonate.
    el-On J; Rubinstein N; Kernbaum S; Schnur LF
    Ann Trop Med Parasitol; 1986 Oct; 80(5):509-17. PubMed ID: 3632098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon gamma therapy for cutaneous leishmaniasis.
    Kürkçüoğlu N; Tandoğdu R
    Arch Dermatol; 1990 Jun; 126(6):831-2. PubMed ID: 2111977
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate.
    Romero GA; Guerra MV; Paes MG; Macêdo VO
    Am J Trop Med Hyg; 2001 Nov; 65(5):456-65. PubMed ID: 11716098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison Of Efficacy Of Miltefosine Versus Meglumine Antimonate In The Treatment Of Cutaneous Leishmaniasis.
    Mohammad N; Sagheer F; Paracha MM; Khan AQ; Naseem S; Wasim M
    J Ayub Med Coll Abbottabad; 2022; 34(4):849-853. PubMed ID: 36566412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.